A letter about ALS TDI's 2026 research priorities from ALS TDI's CEO and Chief Scientific Officer, Fernando Vieira.

A letter about the progress of AP-101 from ALS TDI's CEO and Chief Scientific Officer, Fernando Vieira.

In the months leading up to the 2026 Tri-State Trek, we will be publishing perspectives some of the event's most dedicated supporters about why they ride and what the Trek means to them. Today, we're featuring a letter from Liz Coccio of the team HAS Mamas.

Running the TCS New York City Marathon was, by far, the most important race of Connor’s running career — but not just because of the event’s prestigious status. This time, he was running to support research to find effective treatments for ALS at the ALS Therapy Development Institute (ALS TDI).

The ALS Therapy Development Institute (ALS TDI) is proud to announce that it will lead all research operations for Champion Insights—a new study planned to launch this fall in partnership with Answer ALS and Augie’s Quest to Cure ALS. This effort aims to uncover critical genetic and metabolic factors that may help explain the significantly higher incidence of amyotrophic lateral sclerosis (ALS) among endurance athletes, military service members, and other potentially high-risk groups.

The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world.